BioMind Files Confidential IPO Prospectus: Committed to Clinical-Driven AI Innovation

Li Jingjue, Senior Partner and Greater China CEO at Biomind

“Only through steadfast investment in research and development can products better align with clinical application scenarios, thereby delivering greater clinical and market value,” stated Ms. Li Jingjue at the Global AI Health Summit. “The application scenarios of AI are determined by actual clinical needs, and these scenarios, in turn, define the direction of product R&D.”

Ms. Li Jingjue stated, “In the field of computer-aided diagnosis, BioMind’s strategy is to adopt a ‘whole-body’ approach, starting from the ‘head.’” The development of BioMind’s “Tianyi Zhi” began with neurological diseases of the head, then expanded to otolaryngology and breast imaging, and further to cardiovascular, cerebrovascular, and other thoracic and abdominal conditions, thereby achieving AI-powered CT/MRI applications across multiple anatomical regions and a comprehensive range of diseases. This progression was driven by the practical demands of clinical application scenarios.

Ms. Li Jingjue introduced that, in the field of neurological disorders, BioMind’s “Tianyi Zhi” has pioneered the global implementation of AI-assisted diagnosis for CT and MRI imaging of neurological conditions. It covers more than 60 diseases, including brain tumors, small vessel disease, and stroke, achieving a diagnostic accuracy rate exceeding 90%, with certain conditions surpassing 96%. This technology effectively assists physicians in enhancing both diagnostic efficiency and quality.

It is reported that “Tianyi Zhi” has obtained CE certification from the European Union and secured sales approvals in 26 countries, including Germany, Southeast Asian nations, Singapore, and Malaysia. Currently, “Tianyi Zhi” has completed clinical trials. The U.S. Food and Drug Administration (FDA) has accepted Ande Medical Intelligence’s application, and the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has also accepted the application for a Class III medical device registration certificate for “Tianyi Zhi.”

“In addition to assisting with diagnosis, we have just launched Tianze, an AI-powered clinical decision support system for cerebrovascular diseases this year,” introduced Ms. Li Jingjue. “Tianze” represents a powerful integration of AI and CDSS (Clinical Decision Support System), providing end-to-end decision support across diagnosis, treatment, and prognosis, serving as a comprehensive AI assistant for the entire diagnostic and therapeutic journey in cerebrovascular disease management.

“AI’s original intent is to better align with clinical applications, and we hope to stay true to that mission,” said Ms. Li Jingjue. Going forward, more time and energy will be devoted to refining products, developing AI solutions that are more practical and better suited to clinical needs.